2014 Hot Topic Symposium II: Managing Engineered T Cell ToxicitiesNovember 9, 2014Gaylord National Hotel & Convention Center National Harbor, MDProgram OrganizersKristen Hege, MD – Celgene and University of California, San Francisco Peter Emtage, MD – Medimmune/AstraZeneca Program SummaryFrom the Society for Immunotherapy of Cancer (SITC), these enduring materials from the 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities reviewed the safety experience with CAR T cells and engineered TCR T cells treating hematologic and solid tumor indications, with a specific focus on the unique toxicities described above. Faculty provided guidance on T cell engineering considerations, protocol eligibility restrictions, and special safety monitoring, grading and management guidelines to minimize risk associated with these novel T cell therapies. #HematologicMalignancies #PresentationSlides #Video #AnnualMeeting #HotTopic #SITC#AdoptiveCellTherapy #AdverseEvents #Toxicities #Clinician #Industry #Oncologist #Researcher #2014
Meeting: 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities; Presentation: Toxicity and Management after CTL019 Therapy: Update from University of Pennsylvania; Presenter: James N. Kochenderfer, MD – National Cancer Institute; Date: November 9, 201400:16:59
Meeting: 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities; Presentation: Anti-CD19 CAR T Cells: The Balance of Efficacy and Toxicity; Presenter: James N. Kochenderfer, MD – National Cancer Institute; Date: November 9, 201400:13:41
Meeting: 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities; Presentation: Fred Hutchinson Cancer Research Center Experience; Presenter: Michael C.V. Jensen, MD – University of Washington; Date: November 9, 201400:10:00
Meeting: 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities; Presentation: Cytokine Storm in T Cell Studies - An Update from Baylor University; Presenter: Helen E. Heslop, MD – Baylor College of Medicine; Date: November 9, 201400:05:30
Meeting: 2014 Hot Topic Symposium II: Managing Engineered T Cell Toxicities; Presentation: FDA – History of Immune-Related Adverse Effects from the Regulatory Perspective; Presenter: Bindu George, MD – U.S. Food and Drug Administration; Date: November 9, 201400:14:14
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us